exv10w2



 





EXHIBIT 10.2




TERMINATION AGREEMENT




     This Termination Agreement (the “Termination Agreement”) dated as of June 6, 2007 (the
“Effective Date”) is an amendment to the Development, Commercialization and Marketing Agreement
(the “Agreement”) dated as of December 23, 2002 by and between Altus Pharmaceuticals Inc. (the
successor in interest to Altus Biologics Inc.), a Delaware corporation, with its principal office
at 125 Sidney Street, Cambridge, MA 02139 USA (“ALTUS”) and Dr. Falk Pharma GmbH, a German
corporation, with its principal office at Leinenweberstrasse 5, 79041 Freiberg Germany (“FALK”).



BACKGROUND




     The Parties have concluded that it is in their strategic interest to discontinue their
collaboration and terminate the Agreement. This Termination Agreement sets forth the terms and
conditions applicable to such termination as well and any rights and obligations that survive such
termination. All capitalized terms not expressly defined in this Termination Agreement shall have
the meaning assigned to them in the Agreement.



AGREEMENT




     NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements
herein contained, and for other good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, the Parties, intending to be legally bound, agree as follows:



ARTICLE 1.

TERMINATION




     1.1 Effective Date. As of the Effective Date, the Agreement is terminated, and except as
expressly provided for in Section 1.3 below, all licenses, rights and obligations of the Parties
under the Agreement are terminated.



     1.2 Payments. ALTUS agrees to make the following payments on the following dates to FALK:




	 	1.2.1	 	Five Million Euros (€5,000,000) thirty (30) days following
the Effective Date.
	 
	 	1.2.2	 	Two Million Euros (€2,000,000) on the first anniversary of
the Effective Date.




1









 












	 	1.2.3	 	Two Million Euros (€2,000,000) on the second anniversary of
the Effective Date.
	 
	 	1.2.4	 	Three Million Euros (€3,000,000) on the third anniversary of
the Effective Date.




ALTUS shall have the option, in its discretion, to prepay the payments set forth in clauses 1.2.2,
1.2.3, and 1.2.4. Any late payments shall accrue interest, to the extent permitted by applicable
law, with such interest payment calculated at the Prime rate as reported in the Wall Street
Journal.




     1.3 Surviving Obligations. Notwithstanding Article 14 of the Agreement, the sole surviving
rights and obligations of the Parties shall consist of:




	 	1.3.1	 	The express rights and obligations of the Parties under this
Termination Agreement.
	 
	 	1.3.2	 	The obligations and rights of the Parties set forth in the
Agreement in Articles 10, 15 (solely as to Losses arising out of the surviving
rights and obligations after the Effective Date), and 16, and in Sections
17.1, 17.4, 17.5, 17.6, 17.7, 17.8, 17.9, 17.10, 17.11, 17.12, 17.13 and
17.14.





     1.4 Return or Destruction of Confidential Information; Transfer of Regulatory File and Orphan
Medicinal Product Designation. FALK agrees to deliver copies of all written communications with
the EMEA in its files pertaining to the Licensed Product within thirty (30) days of receiving the
payment specified in subsection 1.2.1 above (the “First Payment”). FALK agrees to make all
reasonable efforts within its control to assign and transfer, to the extent permitted under
applicable law, to ALTUS or its designee within ninety (90) days of the First Payment, the July 22,
2004 Orphan Medicinal Product Designation granted to FALK by the EMEA with respect to the Licensed
Product and any amendments thereto. Each of the Parties agrees to return or destroy all other
Confidential Information of the other Party in its possession within thirty (30) days of the First
Payment, subject to ALTUS having the right to retain any Confidential Information of Falk that is
the subject of the license grant in Section 1.5.1, below.



1.5 Freedom to Operate.





	 	1.5.1	 	FALK hereby grants ALTUS a fully-paid, perpetual, worldwide
non-exclusive license, with the right to sublicense, under (a) any
Confidential Information or know-how provided to ALTUS under the Agreement in
connection with the Licensed Product prior to the date of this Termination
Agreement or (b) any patent or patent rights arising out of the Agreement and
existing as of the date of




2









 






	 	 	 	this Termination Agreement for making, using, importing or selling or
offering to sell the Licensed Product.






	 	1.5.2	 	For avoidance of doubt, the license grant in Section 1.5.1
does not obligate FALK to transfer any information, know-how or technology to
ALTUS.





     1.6 Due Authority. Each Party represents and warrants that it possesses the requisite
corporate right, power and authority to execute and deliver this Termination Agreement and to
perform its obligations under this Termination Agreement.



     1.7 Mutual Releases.




	 	1.7.1	 	As a material inducement to enter into this Termination
Agreement, and for the good and valuable consideration described herein, ALTUS
hereby releases and forever discharges FALK, its affiliates and subsidiaries,
and the representatives, agents, servants, officers, directors, and employees
of the foregoing, from any and all actions, causes of action, costs, damages,
losses, claims, liabilities or demands, of whatsoever character, nature, and
kind, whether known, unknown, suspected, or unsuspected, matured or
contingent, whether specifically mentioned herein or not, which ALTUS now owns
or holds, or any time heretofore held or owned, by and between the Parties
hereto arising directly or indirectly from and/or in connection with the
Agreement.
	 
	 	1.7.2	 	As a material inducement to enter into this Termination
Agreement, and for the good and valuable consideration described herein, FALK
hereby releases and forever discharges ALTUS, its affiliates and subsidiaries,
and the representatives, agents, servants, officers, directors and employees
of the foregoing, from any and all actions, causes of action, costs, damages,
losses, claims, liabilities or demands, of whatsoever character, nature, and
kind, whether known, unknown, suspected, or unsuspected, matured or
contingent, whether specifically mentioned herein or not, which FALK now owns
or holds, or any time heretofore held or owned, by and between the Parties
hereto arising directly or indirectly from and/or in connection with the
Agreement.





[Signatures on next page]




3









 








     IN WITNESS WHEREOF, the parties hereto have executed this Termination Agreement as of the date
set forth above.



	 	 	 	 	 
	ALTUS PHARMACEUTICALS, INC.

 	 	 
	By:  	/s/ Sheldon Berkle
 	 	 
	 	Name:  	Sheldon Berkle 	 	 
	 	Title:  	President and Chief Executive Officer 	 	 
	 
	DR. FALK PHARMA GMBH

 	 	 
	By:  	/s/ Ursula Falk
 	 	 
	 	Name:  	Ursula Falk 	 	 
	 	Title:  	Managing Director 	 	 
	 




4